Drug Shortage Report for VIOKACE

Last updated on 2023-08-03 History
Report ID 191469
Drug Identification Number 02241933
Brand name VIOKACE
Common or Proper name Pancrelipase
Company Name NESTLE ENTERPRISES S.A.
Market Status MARKETED
Active Ingredient(s) AMYLASE PROTEASE LIPASE
Strength(s) 113400UNIT 112500UNIT 20880UNIT
Dosage form(s) TABLET
Route of administration ORAL ORAL
Packaging size 100 tablet bottles
ATC code A09AA
ATC description DIGESTIVES, INCL ENZYMES
Reason for shortage Shortage of an active ingredient.
Anticipated start date 2023-05-03
Actual start date 2023-05-04
Estimated end date
Actual end date 2023-08-02
Shortage status Resolved
Updated date 2023-08-03
Company comments Nestlé Enterprises S.A. are pleased to confirm supply availability has been restored of Viokace 20,880 tablets effective August 2, 2023. There has been no impact on availability of the 10,440 strength.
Health Canada comments
Tier 3 Status No
Contact Address 12, RUE ENTRE-DEUX-VILLES
VEVEY, --
SWITZERLAND 1800
Company contact information kfeltmate@apcipharma.com

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v17 2023-08-03 English Compare
v16 2023-08-02 French Compare
v15 2023-08-02 English Compare
v14 2023-08-02 English Compare
v13 2023-05-08 French Compare
v12 2023-05-08 English Compare
v11 2023-05-05 English Compare
v10 2023-05-04 French Compare
v9 2023-05-04 English Compare
v8 2023-05-04 English Compare
v7 2023-05-02 French Compare
v6 2023-05-02 English Compare
v5 2023-05-02 French Compare
v4 2023-05-02 English Compare
v3 2023-05-02 French Compare
v2 2023-05-02 French Compare
v1 2023-05-02 English Compare

Showing 1 to 17 of 17